Targeting TDP-43 Phase Separation Through Selective RNA-Binding Modulation

Targeting TDP-43 Phase Separation Through Selective RNA-Binding Modulation I propose a novel therapeutic paradigm for ALS-FTD that focuses on selectively disrupting pathological TDP-43 phase separation while preserving physiological condensate formation. The key insight is that disease-associated TDP-43 mutations alter the protein's RNA-binding specificity, creating aberrant protein-RNA networks that drive toxic phase transitions. Rather than broadly inhibiting TDP-43 aggregation, we should target the specific RNA sequences and secondary structures that stabilize pathological condensates. My central hypothesis is that disease-specific TDP-43 variants exhibit altered affinity for cryptic splice sites and repetitive RNA elements, creating a distinct "pathological RNA interactome" that can be therapeutically targeted. Normal TDP-43 condensates are dynamic and functional, regulated by high-affinity binding to UG-rich sequences in pre-mRNAs (PMID:21358617). However, ALS-associated mutations like A315T and M337V reduce this high-affinity binding while increasing promiscuous interactions with low-complexity RNA sequences (PMID:30449892).

Targeting TDP-43 Phase Separation Through Selective RNA-Binding Modulation I propose a novel therapeutic paradigm for ALS-FTD that focuses on selectively disrupting pathological TDP-43 phase separation while preserving physiological condensate formation. The key insight is that disease-associated TDP-43 mutations alter the protein's RNA-binding specificity, creating aberrant protein-RNA networks that drive toxic phase transitions. Rather than broadly inhibiting TDP-43 aggregation, we should target the specific RNA sequences and secondary structures that stabilize pathological condensates. My central hypothesis is that disease-specific TDP-43 variants exhibit altered affinity for cryptic splice sites and repetitive RNA elements, creating a distinct "pathological RNA interactome" that can be therapeutically targeted. Normal TDP-43 condensates are dynamic and functional, regulated by high-affinity binding to UG-rich sequences in pre-mRNAs (PMID:21358617). However, ALS-associated mutations like A315T and M337V reduce this high-affinity binding while increasing promiscuous interactions with low-complexity RNA sequences (PMID:30449892). This shift creates more stable, less dynamic condensates that transition toward irreversible aggregates. The therapeutic strategy involves antisense oligonucleotides (ASOs) or small molecules that compete for binding to the aberrant RNA partners of mutant TDP-43. By selectively sequestering the RNA species that drive pathological phase separation—particularly GC-rich repeats and cryptic polyadenylation signals—we can rebalance the protein-RNA interaction network. This approach would restore normal condensate dynamics without completely disrupting TDP-43's essential splicing functions. Crucially, this strategy explains why broad TDP-43 reduction therapies have shown limited success: they eliminate both pathological and physiological functions indiscriminately. The mechanism predicts that effective therapeutics will show cell-type specificity, with greatest efficacy in motor neurons and cortical neurons that express high levels of the problematic RNA targets. This selective vulnerability aligns with the clinical presentation of ALS-FTD and suggests why previous pan-neuronal approaches have failed to achieve meaningful clinical benefit. ## Supporting Evidence The evidence supporting this hypothesis spans multiple converging lines of research: TDP-43 RNA-binding specificity changes with disease mutations: Studies

Debate provenance: derived from debate `DA-2026-04-11-093252-90e0375b` on question: TDP-43 phase separation therapeutics for ALS-FTD. Consensus signal: domain_expert, falsifier, skeptic, synthesizer, theorist discussed the mechanism terms A315T, ALS, ALS-FTD, FTD, M337V, Modulation, PMID, Phase. Novelty signal: skeptic-discussed-with-qualified-concession.